Analyst Activity – Wedbush Initiates Coverage On Corvus Pharmaceuticals (NASDAQ:CRVS) With a Outperform

ME Staff
-
0

Analyst Ratings For Corvus Pharmaceuticals (NASDAQ:CRVS)

Today, Wedbush initiated coverage on Corvus Pharmaceuticals (NASDAQ:CRVS) with a Outperform.

There are 4 buy ratings on the stock.

The current consensus rating on Corvus Pharmaceuticals (NASDAQ:CRVS) is Buy (Score: 3.00) with a consensus target price of $21.00 per share, a potential 77.36% upside.

Some recent analyst ratings include

  • 8/2/2017-Wedbush initiated coverage with a Outperform rating.
  • 7/4/2017-Cowen and Company Reiterated Rating of Outperform.
  • 4/5/2017-Cantor Fitzgerald Reiterated Rating of Buy.
  • 6/2/2016-BTIG Research initiated coverage with a Buy rating.
  • 4/18/2016-Guggenheim initiated coverage with a Buy rating.


  • On 6/23/2017 Holdings A/S Novo, Major Shareholder, bought 20,000 with an average share price of $10.95 per share and the total transaction amounting to $219,000.00. View SEC Filing
  • On 6/13/2017 Richard A Md Miller, Insider, bought 25,000 with an average share price of $9.88 per share and the total transaction amounting to $247,000.00. View SEC Filing
  • On 6/24/2016 Orbimed Advisors Llc, Director, bought 1,000 with an average share price of $12.98 per share and the total transaction amounting to $12,980.00. View SEC Filing
  • On 6/21/2016 Orbimed Advisors Llc, Director, bought 38,383 with an average share price of $12.75 per share and the total transaction amounting to $489,383.25. View SEC Filing
  • On 6/16/2016 Orbimed Advisors Llc, Director, bought 20,000 with an average share price of $12.35 per share and the total transaction amounting to $247,000.00. View SEC Filing
  • On 6/10/2016 Peter A Thompson, Director, bought 50,000 with an average share price of $12.96 per share and the total transaction amounting to $648,000.00. View SEC Filing
  • On 5/20/2016 Orbimed Advisors Llc, Director, bought 4,716 with an average share price of $13.09 per share and the total transaction amounting to $61,732.44. View SEC Filing

Recent Trading Activity for Corvus Pharmaceuticals (NASDAQ:CRVS)
Shares of Corvus Pharmaceuticals closed the previous trading session at 11.84 down -0.25 -2.07% with 16,181 shares trading hands.